Genelux Investor Presentation Deck

Clinically-Meaningful Responses in Heavily Pretreated Patients Key Clinical Takeaways Promising ORR and PFS, and clinical reversal of platinum resistance and refractoriness among patients with PRROC ● ● All patients had documented progressive disease at enrollment Overall response rate in 27 patients was 54% with 7.6- month median duration of response Historical PFS in this patient population is ~4 mos GENELUX Overall Response Rate (ORR) & Progression-Free Survival (PFS)* ORR by RECIST 1.1** ORR by CA-125 Median PFS All patients (n=27) (95% CI) Platinum-resistant (n=14) (95% CI) Platinum-refractory (n=13) (95% CI) 54% (13%24) (33-74) 55% (6/11) (26-84) 54% (7/13) (27-81) Duration Response 7.6 mos (3.7 - 9.6) 7.6 mos (3.7 - NA) 8.0 mos (3.7 - NA) 85% (22/26) (65 - 96) 85% (11/13) (55-98) 85% (11/13) (55-98) 11.0 mos (6.7 - 13.0) 10.0 mos (6.4 - NA) 11.4 mos (4.3 -13.2) Median OS 15.7 mos (12.3 - 23.8) 18.5 mos (11.323.8) 14.7 mos (10.8 -33.6) *Baseline for ORR & PFS evaluation is the timepoint immediately prior to starting post-Olvi- Vec carboplatin doublet +/- bevacizumab to allow direct comparison to historical data or patients' own previous line of chemotherapy **Eligible for evaluation: with at least 1 measurable target lesion at baseline; including 2 patients without post-chemo scan after virotherapy, and therefore are assigned to the 'inevaluable for response' category per RECIST1.1 "Including 3 unconfirmed; 2 in resistant and 1 in refractory groups 13

View entire presentation